Literature DB >> 2018725

The spectrum of malignant melanoma of the nail apparatus.

R P Dawber1, G B Colver.   

Abstract

Unlike most morphological types of malignant melanoma, that of the nail apparatus is relatively rare--only 2% to 3% of one series. Although in the case of blacks and orientals, the incidence of malignant melanoma of the nail apparatus is proportionately more common. However, it is a serious disease with poor 5-year survival figures in the published series--21% to 50%. This poor prognosis may be an intrinsic function of the site and of other parts of the body, but the lateness of diagnosis in many of the published cases is of far more significance. In malignant melanoma at other body sites, late diagnosis usually relates to the patient not presenting early in the course of the disease; this may also apply to nail malignant melanoma. However, the frequency of failure of the first line physician or surgeon to recognize the clinical signs or to perform a biopsy from the correct site to obtain an accurate diagnosis is far more important.

Entities:  

Mesh:

Year:  1991        PMID: 2018725

Source DB:  PubMed          Journal:  Semin Dermatol        ISSN: 0278-145X


  3 in total

1.  Development of a practical guide for the early recognition for malignant melanoma of the foot and nail unit.

Authors:  Ivan R Bristow; David Ar de Berker
Journal:  J Foot Ankle Res       Date:  2010-09-28       Impact factor: 2.303

2.  Acral Lentiginous Melanoma, Indolent Subtype Diagnosed by En Bloc Excision: A Case Report.

Authors:  Jungyoon Ohn; Jeong Mo Bae; Ji Soo Lim; Jong Seo Park; Hyun-Sun Yoon; Soyun Cho; Hyun-Sun Park
Journal:  Ann Dermatol       Date:  2017-05-11       Impact factor: 1.444

3.  Confirmatory trial of non-amputative digit preservation surgery for subungual melanoma: Japan Clinical Oncology Group study (JCOG1602, J-NAIL study protocol).

Authors:  Kiyo Tanaka; Yasuhiro Nakamura; Tomonori Mizutani; Taro Shibata; Arata Tsutsumida; Haruhiko Fukuda; Shigeto Matsushita; Megumi Aoki; Kenjiro Namikawa; Shuichi Ohe; Satoshi Fukushima; Naoya Yamazaki
Journal:  BMC Cancer       Date:  2019-10-25       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.